{'fraction_non_alphanumeric': 0.036511156186612576, 'fraction_numerical': 0.06288032454361055, 'mean_word_length': 4.67816091954023, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
In Vitro Activity of the Oxazolidinone RWJ-416457 against Linezolid-Resistant and -Susceptible Staphylococci and Enterococci

ABSTRACT RWJ-416457, a novel oxazolidinone, had modal MICs of 0.5 to 1 μg/ml for linezolid-susceptible staphylococci and enterococci, versus linezolid MICs for these organisms of 1 or 2 μg/ml. RWJ-416457 MICs for mutants with 23S rRNA mutations were 2 to 32 μg/ml, versus linezolid MICs of 8 to 64 μg/ml; actual values reflected the proportion of gene copies mutated.